ISSN: 1300-7777 E-ISSN: 1308-5263
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report [Turk J Hematol]
Turk J Hematol. 2015; 32(2): 180-183 | DOI: 10.4274/tjh.2013.0338  

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Meltem Aylı1, Muhit Özcan2, Güldane Cengiz Seval1
1Ufuk University Faculty of Medicine, Department of Hematology, Ankara, Turkey
2Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey

A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.

Keywords: Primary myelofibrosis, Ruxolitinib, Splenectomy


Konvansiyonel Tedavilere ve Splenektomiye Refrakter Primer Myelofibrozisli Olguda Ruxolitinib Deneyimi

Meltem Aylı1, Muhit Özcan2, Güldane Cengiz Seval1
1Ufuk University Faculty of Medicine, Department of Hematology, Ankara, Turkey
2Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey

Dört yıl önce primer myelofibrozis tanısı konulan 67 yaşındaki erkek hastaya uygulanan konvansiyonel tedavi yöntemleri ile sonuç alınamadı. Dalak boyutları ileri derecede arttı, hastanın tekrar ayda 4-6 ünite transfüzyon gereksinimi olmaya başladı. Bu dönemde dev boyutlara ulaşan dalakta infarktüs gelişti ve hastaya splenektomi yaptırıldı. Splenektomi sonrası hastaya ruxolitinib başlandı. Ruxolitinib tedavisinin 1. ayından itibaren hasta transfüzyon bağımsız hale geldi, tüm konstitüsyonel semptomlar ortadan kalktı. Ancak ruxolitinib tedavisinin 6. ayında hasta akut myeloblastik lösemiye (AML) transfore oldu. Ve AML tedavisinin 1. ayında hasta kaybedildi. Bu olgu splenektomi yapılmış bir hastada ruxolitinib etkisini gösteren ilk olgudur.

Anahtar Kelimeler: Primer myelofibrozis, Ruxolitinib, Splenektomi


Meltem Aylı, Muhit Özcan, Güldane Cengiz Seval. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report. Turk J Hematol. 2015; 32(2): 180-183

Corresponding Author: Güldane Cengiz Seval, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686